Black Currant for Health & Longevity - Quick Reference Sheet

Black Currant for Health & Longevity

Created on 10/17/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Black currant is a purple berry yielding oral extract and seed oil supplements for exercise, blood flow, and immunity. Sufficient or multi-day extracts strongly improve fat burning, artery flexibility, and mealtime blood sugar and moderately support bones and eyes; seed oil moderately supports joints and immunity. Gut, blood pressure, cholesterol, and memory evidence is low and conflicted, longevity is confined to yeast and mice, and capsules avoid tooth erosion. (Full Review)

Protocol

Standard cardiometabolic and exercise protocol
300–600 mg/day extract
105–210 mg/day standardized New Zealand anthocyanins for fat oxidation, insulin sensitivity, and vascular function
Whole-fruit MAO-B and seed oil protocols
3–4.5 g/day seed oil or 500 mg polyphenols
450–720 mg/day gamma-linolenic acid for anti-inflammatory support; berry powder or juice (~7.8 mg/kg anthocyanins) for MAO-B inhibition
Optimal time of day
1–2 h pre-exercise or immediately pre-meal
1–2 hours pre-exercise to match peak plasma vasodilation windows, or 600–711 mg anthocyanins before high-carbohydrate or high-fat meals
Time to effect
Fat oxidation and insulin sensitivity
7–8 days
+22% insulin sensitivity, -8% to -9% post-meal glucose, +0.042 g/min exercise fat oxidation (+27% in women), and +0.45% sports performance (Cohen's d = 0.44)
Glycemic blunting, vision, and MAO-B inhibition
1–2 hours
Post-meal glucose (-0.34 mmol/L·h) and GIP (-46.6 ng/L·h) blunting, dark adaptation (-0.120 log μcd/m²), and 89%–91% platelet MAO-B inhibition
Immunity, bone, and glaucoma
4–8 weeks to 24 months
T-cell immunity and -27 percentage points PGE2 synthesis (4–8 weeks); +0.014 g/cm² whole-body BMD (6 months); glaucoma visual field preservation (24 months)

Benefits

Contraindications
  • Active bleeding, hemophilia, or scheduled surgery (within 14 days)
  • Prescription monoamine oxidase inhibitors (phenelzine, selegiline, rasagiline) or unstable psychiatric disorders
  • Uncontrolled hypertension (blood pressure ≥160/100 mmHg), fasting glucose ≥7.1 mmol/L, fasting triglycerides ≥5.0 mmol/L, total cholesterol ≥7.5 mmol/L, or active liver, kidney, or gastrointestinal disease
  • Known allergy or hypersensitivity to Ribes nigrum berries or seed oil
Key Interactions
  • Serotonergic drugs (sertraline; human pharmacodynamic data, clinical toxicity theoretical)
  • Prescription anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel; theoretical bleeding risk from human biomarker data)
  • Antihypertensive and antidiabetic drugs (lisinopril, amlodipine, metformin, glipizide; theoretical additive effect)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen; theoretical additive antiplatelet effect)
  • Antiplatelet, vasodilatory, and antiglycemic supplements (fish oil, Ginkgo, berberine, L-theanine; theoretical additive effect)
  • Phytic acid (inositol hexaphosphate) and topoisomerase I chemotherapeutics (irinotecan; human pharmacokinetic data for phytic acid, theoretical for irinotecan)

Risk & Side Effects

  • High:
  • Medium: Dental enamel erosion from unbuffered juice formulations
  • Low: Gastrointestinal distress and soft stools; platelet aggregation inhibition and bleeding tendency
  • Speculative: Leukocyte pro-apoptotic shift during exertional heat stress; interference with topoisomerase-targeting chemotherapy

Monitoring

Marker Target Why
Fasting Glucose & HOMA-IR Glucose: 70–99 mg/dL (standard reference range); HOMA-IR: No established target; tracked via reduction from individual baseline Efficacy marker: 8-day extract (600 mg/day) improves insulin sensitivity by 22% and lowers post-meal glucose excursions.
Fasting Triglycerides <150 mg/dL (standard reference range) Efficacy marker: 6-month extract (784 mg/day) dose-dependently lowers fasting plasma triglycerides.
hs-CRP <3.0 mg/L (standard reference range) Efficacy marker: anthocyanin supplementation reduces systemic hs-CRP in overweight and metabolic syndrome adults.
Whole-Body BMD (DXA) & Serum P1NP Whole-body BMD: No established target; tracked for stability or gain vs. baseline; P1NP: 19–83 μg/L (standard reference range) Efficacy marker: 784 mg/day extract preserves 6-month whole-body BMD and elevates P1NP in menopausal women.
Intraocular Pressure & Humphrey Visual Field MD Intraocular pressure: 10–21 mmHg (standard reference range); Visual field MD: No established target; tracked for stability versus baseline Efficacy marker: 50 mg/day anthocyanins slow visual field MD deterioration and lower intraocular pressure.
INR / Prothrombin Time (anticoagulated users) 0.8–1.1 (standard reference range) Safety check: anthocyanins and seed oil inhibit platelet activation and may potentiate anticoagulant bleeding risk.

Cadence: Baseline; 1–2 weeks for acute glycemic/exercise responses and INR (after starting or stopping in warfarin users); 8 weeks and every 3–6 months for fasting metabolic, triglyceride, and hs-CRP panels; every 6–12 months for DXA bone density, serum P1NP (6 months), and ophthalmic visual field/tonometry (every 6 months).

Qualitative Assessment

  • Exercise recovery: Submaximal heart rate and post-workout muscle soreness during 7-day loading.
  • Visual comfort: Evening eye strain and dim-light adaptation following prolonged screen work.
  • Digestive and hemostatic tolerance: Stool consistency, eructation, and unexpected bruising.